Literature DB >> 16601874

Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.

A El-Beshlawy1, L Ragab, I Youssry, K Yakout, H El-Kiki, K Eid, I M Mansour, S Abd El-Hamid, M Yang, P K Mistry.   

Abstract

BACKGROUND: In Gaucher disease, the infiltration of the bone marrow by glucocerebroside-laden macrophages (Gaucher cells) triggers a diverse pattern of skeletal disease that results in crippling complications. Reliable ascertainment of the severity and pattern of skeletal disease is essential to determine disease status and the response to enzyme replacement therapy (ERT). Although there is ample documentation of reversal of haematological and visceral disease by ERT, there is a paucity of data on skeletal response to ERT in children. AIM: To delineate the pattern of bone disease in children with Gaucher disease in Egypt and to evaluate its response to ERT.
METHOD: Twenty-two children with Gaucher disease were treated with ERT. Phenotyping by clinical, laboratory and radiological criteria was performed at baseline and following 11.2 +/- 4 months of ERT. Genotyping for glucocerebrosidase (GBA) mutations was performed by gene sequencing, and genotype-phenotype correlations were performed.Results. Two-thirds of the patients were from consanguineous pedigrees and 14/22 patients were homozygous or compound heterozygous for L444P and D409H mutations. Bone involvement was detected by plain radiology in 11 children (50%) and in 16 (73%) by magnetic resonance imaging (MRI). There was no correlation of severity of bone involvement and GBA genotype. ERT ameliorated bone disease: 10 of the 11 children with abnormal radiographic findings at baseline showed improvement in skeletal lesions; while 9/16 showed improvement of marrow disease by MRI. Radiographic sensitivity and specificity were 62% and 82% compared to MRI for detection of bone involvement in this patient population. At baseline, bone pain was present in 5 patients and ERT resulted in complete symptomatic remission in all of them. ERT was associated with significant improvement in growth parameters and amelioration of haematological and visceral involvement.
CONCLUSION: Symptomatic and radiological skeletal disease is common in children with Gaucher disease in Egypt. MRI is the most accurate technique for detecting early skeletal involvement. There was no correlation between severity of skeletal involvement and GBA genotype. ERT was effective in ameliorating radiological manifestations of skeletal disease and achieving complete remission of bone pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601874     DOI: 10.1007/s10545-006-0121-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

1.  Introduction. Advances in Gaucher Disease: therapeutic goals and evaluation and monitoring guidelines.

Authors:  Neal J Weinreb
Journal:  Semin Hematol       Date:  2004-10       Impact factor: 3.851

2.  Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement.

Authors:  D Elstein; I Hadas-Halpern; M Itzchaki; A Lahad; A Abrahamov; A Zimran
Journal:  Blood Cells Mol Dis       Date:  1996       Impact factor: 3.039

3.  [French results of enzyme replacement therapy in Gaucher's disease].

Authors:  Gérard Schaison; Isabelle Caubel; Nadia Belmatoug; Thierry Billette de Villemeur; Jean-Marie Saudubray
Journal:  Bull Acad Natl Med       Date:  2002       Impact factor: 0.144

4.  Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.

Authors:  R Kauli; R Zaizov; L Lazar; A Pertzelan; Z Laron; A Galatzer; M Phillip; Y Yaniv; I J Cohen
Journal:  Isr Med Assoc J       Date:  2000-02       Impact factor: 0.892

Review 5.  Bone complications in children with Gaucher disease.

Authors:  B Bembi; G Ciana; E Mengel; M R Terk; C Martini; R J Wenstrup
Journal:  Br J Radiol       Date:  2002       Impact factor: 3.039

6.  55-base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles.

Authors:  N Tayebi; H Stern; I Dymarskaia; J Herman; E Sidransky
Journal:  Am J Med Genet       Date:  1996-12-18

Review 7.  Bone and joint complications related to Gaucher disease.

Authors:  G M Pastores; M J Patel; H Firooznia
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.592

8.  Chitotriosidase as a marker of macrophage stimulation.

Authors:  T A Korolenko; S Y Zhanaeva; O V Falameeva; V I Kaledin; E E Filyushina; I I Buzueva; G A Paul
Journal:  Bull Exp Biol Med       Date:  2000-10       Impact factor: 0.804

9.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.

Authors:  Neal J Weinreb; Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Ari Zimran
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

Review 10.  Gaucher disease: complexity in a "simple" disorder.

Authors:  Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

View more
  17 in total

1.  Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.

Authors:  Zakarya El-Morsy; Mohamed T Khashaba; Othman El-Sayed Soliman; Sohier Yahia; Dina Abd El-Hady
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

Review 2.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

Review 3.  Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.

Authors:  Siavash Piran; Dominick Amato
Journal:  J Inherit Metab Dis       Date:  2010-03-25       Impact factor: 4.982

4.  Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.

Authors:  Giovanni Ciana; Laura Deroma; Anna Martina Franzil; Andrea Dardis; Bruno Bembi
Journal:  J Inherit Metab Dis       Date:  2012-03-23       Impact factor: 4.982

5.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

6.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

Review 7.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

8.  Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.

Authors:  P Grigorescu Sido; C Drugan; V Cret; C Al-Kzouz; C Denes; C Coldea; A Zimmermann
Journal:  J Inherit Metab Dis       Date:  2007-08-20       Impact factor: 4.982

9.  Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.

Authors:  Pramod K Mistry; Patrick Deegan; Ashok Vellodi; J Alexander Cole; Michael Yeh; Neal J Weinreb
Journal:  Br J Haematol       Date:  2009-09-03       Impact factor: 6.998

10.  Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; W Henley; K M Wyatt; V Nikolaou; D A Hughes; S Waldek; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-02-11       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.